Fever News and Research RSS Feed - Fever News and Research

Promising results for stem cell therapy in MS

Promising results for stem cell therapy in MS

Preliminary findings suggest that nonmyeloablative haematopoietic stem cell transplantation may arrest, or even reverse, the progress of disease among patients with relapsing–remitting multiple sclerosis. [More]
Antibiotic use by travellers may promote spread of drug-resistant 'super-bacteria'

Antibiotic use by travellers may promote spread of drug-resistant 'super-bacteria'

Treating travellers' diarrhoea with antibiotics can promote the spread of drug-resistant "super-bacteria". [More]
Kaleo, CHMI partner to reduce prescription drug-related deaths

Kaleo, CHMI partner to reduce prescription drug-related deaths

Kaleo, a privately-held pharmaceutical company, today announced a national strategic partnership with the Clinton Health Matters Initiative, an initiative of the Clinton Foundation, that will help support its goal of cutting prescription drug-related deaths in half, saving approximately 10,000 lives over five years. [More]
Raiing Medical, Boston Children's Hospital sign license agreement for Thermia education platform

Raiing Medical, Boston Children's Hospital sign license agreement for Thermia education platform

Raiing Medical Inc. and Boston Children's Hospital entered a license agreement for Boston Children's Thermia education platform, designed to assist parents in learning more about fever, illness and fever management. The online educational framework will be integrated with Raiing's iThermonitor device, a wearable thermometer with US FDA 510(k) clearance. [More]
Taking antibiotics for diarrhea may put travelers at increased risk for contracting superbugs

Taking antibiotics for diarrhea may put travelers at increased risk for contracting superbugs

Taking antibiotics for diarrhea may put travelers visiting developing parts of the world at higher risk for contracting superbugs and spreading these daunting drug-resistant bacteria to their home countries, according to a new study published in Clinical Infectious Diseases and now available online. [More]
Alzheimer's drug Aricept (donepezil) linked to serious side effects

Alzheimer's drug Aricept (donepezil) linked to serious side effects

New warnings have been added to the prescribing information for the Alzheimer's drug Aricept (donepezil) advising of the risk of two rare but potentially serious conditions: muscle breakdown (rhabdomyolysis) and a neurological disorder called neuroleptic malignant syndrome (NMS). [More]
Research breakthrough in understanding mosquito reproductive process

Research breakthrough in understanding mosquito reproductive process

Diseases transmitted by mosquitoes have contributed to the death and suffering of millions throughout human history, earning the mosquito the title as the world's most dangerous animal. Even today, several devastating mosquito-borne diseases (such as malaria, dengue fever and West Nile virus) continue to rage. [More]
Increase in Lassa fever cases could be due to human-to-human transmission, research reveals

Increase in Lassa fever cases could be due to human-to-human transmission, research reveals

One in five cases of Lassa fever - a disease that kills around 5,000 people a year in West Africa - could be due to human-to-human transmission, with a large proportion of these cases caused by 'super-spreaders', according to research published today in the journal PLOS Neglected Tropical Diseases. [More]
Mayo Clinic expert explains difference between severe sepsis and septic shock

Mayo Clinic expert explains difference between severe sepsis and septic shock

Sepsis can be a dangerous complication of almost any type of infection, including influenza, pneumonia and food poisoning; urinary tract infections; bloodstream infections from wounds; and abdominal infections. [More]
ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258. [More]
Study confirms safety of two measles-containing vaccines

Study confirms safety of two measles-containing vaccines

A 12-year study of two measles-containing vaccines, published today in Pediatrics, found that seven main adverse outcomes were unlikely after either vaccine. [More]
Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. [More]
OncoGenex executes initial agreement with Teva to regain rights to custirsen

OncoGenex executes initial agreement with Teva to regain rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers. [More]
Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. [More]
Infectious disease specialist underscores the importance of flu vaccines

Infectious disease specialist underscores the importance of flu vaccines

Flu season is in full swing, but it's not too late to get a flu vaccine. In fact, it's never been easier and more convenient. [More]
FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration approved the intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. [More]
Lilly receives FDA approval for CYRAMZA (ramucirumab)

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). [More]
Two studies shed new light on risks associated with blood transfusions

Two studies shed new light on risks associated with blood transfusions

Two studies published in the January issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists, shed new light on the prevalence of transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO), the number one and two leading causes of blood transfusion-related deaths in the United States. [More]
Study: New flooring can increase risk of respiratory diseases in infants

Study: New flooring can increase risk of respiratory diseases in infants

New flooring in the living environment of pregnant women significantly increases the risk of infants to suffer from respiratory diseases in their first year of life. This is the result of a study carried out by the Helmholtz Centre for Environmental Research and the "St Georg" Municipal Hospital, which demonstrates that exposure to volatile organic compounds in the months before and after birth induces breathing problems in early childhood . [More]
Roche announces launch of cobas Liat System for on-demand testing in different settings

Roche announces launch of cobas Liat System for on-demand testing in different settings

Roche today announced the launch of the cobas Liat System—a fast, compact , easy to use, molecular diagnostic platform, designed for on-demand testing in physician clinics, pharmacies and hospital lab settings. [More]